Deep vein thrombosis (DVT) is a medical condition characterized by the formation of blood clots in the deep veins, typically within the legs. This condition poses a serious health risk as these clots have the potential to break loose and travel through the bloodstream, reaching vital organs such as the lungs, resulting in a life-threatening condition known as pulmonary embolism. DVT often develops when blood flow is restricted or slows down, commonly due to prolonged immobility, surgery, or underlying medical conditions that affect blood clotting. Individuals with a family history of DVT, those who smoke, are obese, or take hormonal medications, such as birth control pills, may be at a higher risk. Symptoms of DVT include pain, swelling, and redness in the affected leg, although some cases may exhibit no noticeable signs. Prompt diagnosis and treatment are crucial to prevent complications, and management often involve blood-thinning medications and lifestyle changes. It is essential for individuals at risk to be aware of the symptoms and seek medical attention if they suspect DVT, especially when engaging in activities that may increase the likelihood of clot formation.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India